Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe - Seite 2

The instillation of chondroitin sulfate (ChS), one of the main components of the GAG layer that is reduced in IC, restores the barrier function. Uracyst^®/Uropol^® 2% 400 mg was developed to specifically replenish this GAG defect in IC/BPS patients.

Uracyst^® 2% (400 mg) ChS dose has been shown to be the ideal dosage to saturate the bladder, thus restoring the barrier function. Instilled fluid volume of 20 mL Uracyst^®/Uropol^® (400mg) also allows patients to retain the treatment in the bladder for a longer period of time, enabling a better uptake of the delivered dosage and a faster onset of symptomatic relief. Uracyst^®/Uropol^® are also one of the most cost effective treatments for these patients. Combine treatment efficacy with the most cost effective therapy and it becomes understandable why Uracyst^®/Uropol^® are becoming the product of choice in treating IC/BPS. Uracyst^®/Uropol^® is sold extensively throughout Canada, Europe and parts of Asia but has not been approved for marketing in the U.S.

About Tribute Pharmaceuticals Canada Inc.

Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.

Tribute markets Cambia^® (diclofenac potassium for oral solution), Bezalip^® SR (bezafibrate), Soriatane^® (acitretin), NeoVisc^® (1.0% sodium hyaluronate solution) Uracyst^®/Uropol^® (sodium chondroitin sulfate solution 2%), Fiorinal^®, Fiorinal^® C, Visken^®, Viskazide^® and Collatamp^® G in the Canadian market. Additionally, NeoVisc^® and Uracyst^® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.